HC Wainwright Reaffirms “Buy” Rating for Evaxion Biotech A/S (NASDAQ:EVAX)

Evaxion Biotech A/S (NASDAQ:EVAX)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $14.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 328.13% from the company’s current price. HC Wainwright also issued estimates for Evaxion Biotech A/S’s FY2029 earnings at $0.11 EPS.

Evaxion Biotech A/S Stock Up 36.3 %

Shares of NASDAQ EVAX opened at $3.27 on Monday. The business has a 50-day moving average price of $4.79 and a 200 day moving average price of $10.58. The stock has a market cap of $3.83 million, a PE ratio of -2.26 and a beta of -0.28. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. Evaxion Biotech A/S has a 52-week low of $2.22 and a 52-week high of $23.70.

Institutional Trading of Evaxion Biotech A/S

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC purchased a new position in shares of Evaxion Biotech A/S (NASDAQ:EVAX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned about 2.98% of Evaxion Biotech A/S as of its most recent SEC filing. 11.04% of the stock is owned by institutional investors.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.